TWi Tells Fed. Circ. Takeda's Dexilant Patent Claims Are Invalid
TWi Pharmaceuticals Inc. pressed the Federal Circuit on Friday to revive its generic version of Takeda Pharmaceutical Co. Ltd.'s acid reflux medicine Dexilant, arguing that Takeda's patent claims for the drug...To view the full article, register now.
Already a subscriber? Click here to view full article